Healios K.K.

Healios K.K. is a biotechnology company focused on the research, development, and manufacture of cell therapy and regenerative medicine products. Established in 2011 and headquartered in Tokyo, Japan, the company targets medical conditions with limited existing treatments, aiming to deliver innovative therapies to patients with unmet medical needs. Healios K.K.'s pipeline includes advanced-stage clinical candidates such as HLCM051, being developed for acute respiratory distress syndrome, ischemic stroke, and trauma, as well as HLCR011 for retinal diseases and HLCN061 targeting solid tumors. Operating primarily in Japan, Europe, and the United States, Healios leverages a network of subsidiaries and research institutions to pursue breakthroughs in regenerative medicine. The company plays a notable role in advancing the field of cellular therapies, positioning itself as a key contributor to the healthcare and biotechnology sectors through its commitment to delivering new modalities for difficult-to-treat illnesses.